All News
Juvenile Idiopathic Arthritis - NEJM Review
Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).
Read Article
2025 BSR Recommendations for ANCA-associated Vasculitis
The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).
Read Article
Rheums Speak - RA Treatment Survey
RheumNow's August 2025 “Live Vote” surveys examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis.
The first survey on RA Treatment (7/28/2025) sheds light on evolving prescribing habits, use of biologics, and key frustrations in RA care.
Retrospective review of 9 #RA pts w/ elevated liver enzymes who were Rx w/ TNF inhibitor (4 adalimumab, 5 etanercept; 78% female, median BMI 37). Over 3 yrs F/U, LFTs declined, fibrosis scores (FIB-4) signif decreased; albumin & bilirubin remained stable https://t.co/Hcwa3qaupv https://t.co/OwGY5jxxyZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Potentially novel RA vaccine of recombinant HLA-DRB1 04:01 bound to type II collagen (COL2) peptide COL2259-273 that was chemically modified at glycine position 265 & shows to suppress collagen induced arthritis in human DRB1 04:01-expressing mice https://t.co/TtBt49DQDa https://t.co/qMXzmvNc1b
Dr. John Cush RheumNow ( View Tweet)
Review of macrophage phenotypes (M1, M2, etc) in rheumatic diseases. In RA synovial Tiss macrophages - are MerTK+CD206+ w/ remission and MerTK−CD206− w/ active inflammation. Tissue fibrosis in PSS driven by Profibrotic CD206+ and CD163+ cell subsets https://t.co/vIG7SYsaWq https://t.co/OKnzOFIlKr
Dr. John Cush RheumNow ( View Tweet)
Pipeline of drugs being developed for Scleroderma by these companies - Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson, Prometic, Cytori arGentis - either as fusion proteins, peptides, small molecule, mAb, Polymern& Gene therapy https://t.co/dWRcQ1a3GU
Dr. John Cush RheumNow ( View Tweet)
A New RA Approval (8.1.2025)
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA
https://t.co/hHNvdOKp2z https://t.co/lUAZM7bY7X
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkdUQclz
a. just getting started…
b. More research &scholarship
c. Growing a successful practice
d. Greater knowledge and expertise
e. Closer to burn-out
Dr. John Cush RheumNow ( View Tweet)
UL nerves. https://t.co/CvqjMC0p0o
Mo Imam MoAImam ( View Tweet)
Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significant differences across sJIA clinical phenotypes, with dynamic changes linked to treatment response over time
ACR Open Rheumatology
https://t.co/GU5y70EXiI https://t.co/oCiKd0INuT
Links:
ACR_Journals ACR_Journals ( View Tweet)
🧵 Vasculitis is Not One Disease – It’s a Spectrum
It’s not a diagnosis.
It’s a mechanism.
From small-vessel purpura to large-vessel aneurysms, here’s how to recognize and reason through the vasculitis spectrum👇
@Amansharmapgi @DurgaPrasannaM1 @12VRavindran @Kanjivellam https://t.co/eEalTpDTGD
Aravind Palraj Rheumat_Aravind ( View Tweet)
Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentially beneficial are sulfasalazine, hydroxychloroquine, & leflunomide. More info needed on IL-6, IL-17/23 inhibitors. Concerns over NSAIDs & JAKi https://t.co/INEdCt0pxa
Dr. John Cush RheumNow ( View Tweet)
Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of de novo heart failure (HF), and no significant risk of HF worsening w/ TNFis. https://t.co/9sRVsMZ1kv https://t.co/Kapg9ZwVGf
Dr. John Cush RheumNow ( View Tweet)
Study of 110 #SLE pts found 41% w/ osteoporosis, 35% of whom had Lupus nephritis (LN). SLE w/ lower BMD assoc w/ LN classes III & IV, U1-RNP Abs, high CRP, & longer Dz duration, also w/ higher age, HAQ, C3 levels. 86% were on glucocorticoids, mean age 48 yrs. https://t.co/dqutqbvnjB
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkdUQclz
a. just getting started…
b. More research &scholarship
c. Growing a successful practice
d. Greater knowledge and expertise
e. Closer to burn-out
Dr. John Cush RheumNow ( View Tweet)
French retrospective observational study of Bx/CT/PET Dx of 380 #GCA pts found 7.6% (29) w/ Nl baseline CRP < 10 mg/L at Dx. GCA w/ low CRP had less fever, more ocular Dz (ant ischemic optic neuropathy 28 vs 13%), & limb claudication (24 vs. 8%) but equal relapse rates https://t.co/fPy92NjJzS
Dr. John Cush RheumNow ( View Tweet)
Annals of Family Medicine pub a machine learning study that predicts clinic "no-shows" w/ 85% accuracy & late cancellations w/ 92% accuracy. Data derived from >1.1 million appointments from 15 family medicine clinics in Pennsylvania between 2019 and 2023. https://t.co/462fwmEGJl https://t.co/n5vIbtKFu0
Dr. John Cush RheumNow ( View Tweet)
CCL17 is a downstream mediator of GM-CSF. Drug repurposing review of FDA approved Rx shows 5 Rx w/ anti-CCL17 effects - fluoxetine, ractopamine, ponesimod, terbutaline & etravirine, w/ inhibition of STAT5, IRF4 & CCL17 & shows antiinflamm effects in RA animal model https://t.co/2aTyZMWPJn
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Vagal Nerve Stimulator for RA
SetPoint Medical announced the FDA approved the SetPoint System, a neuroimmune modulation treatment for moderate-to-severe rheumatoid arthritis (RA), for patients not well-managed or cannot tolerate—existing RA therapies like https://t.co/McheSz30dl
Dr. John Cush RheumNow ( View Tweet)
